{"id":"allovectin-7","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Local inflammation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Allovectin-7 uses a lipid-based vector to transfect tumor cells with genes encoding HLA-B7 and β2-microglobulin, which are human leukocyte antigens that increase tumor immunogenicity. This allows the immune system to better recognize and attack the modified tumor cells. The approach is designed to convert immunologically 'cold' tumors into 'hot' tumors by increasing MHC class I presentation on the tumor cell surface.","oneSentence":"Allovectin-7 is a DNA-based immunotherapy that delivers the HLA-B7 and β2-microglobulin genes directly into tumor cells to enhance immune recognition and rejection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:31.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Cutaneous T-cell lymphoma (mycosis fungoides)"}]},"trialDetails":[{"nctId":"NCT00395070","phase":"PHASE3","title":"A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma","status":"COMPLETED","sponsor":"Vical","startDate":"2006-10","conditions":"Metastatic Melanoma","enrollment":390},{"nctId":"NCT00003646","phase":"PHASE2","title":"Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"Vical","startDate":"1998-08","conditions":"Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma","enrollment":78},{"nctId":"NCT00044356","phase":"PHASE2","title":"Phase II Trial of Allovectin-7® for Metastatic Melanoma","status":"COMPLETED","sponsor":"Vical","startDate":"2001-02","conditions":"Melanoma, Metastatic Melanoma, Malignant Melanoma","enrollment":133},{"nctId":"NCT00003647","phase":"PHASE3","title":"Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"Vical","startDate":"1998-07","conditions":"Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma","enrollment":""},{"nctId":"NCT00050388","phase":"PHASE3","title":"Phase II Trial of Allovectin-7® for Head and Neck Cancer","status":"COMPLETED","sponsor":"Vical","startDate":"","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx, Head and Neck Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"allovectin-7","genericName":"allovectin-7","companyName":"Vical","companyId":"vical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Allovectin-7 is a gene therapy agent being studied for the treatment of various stages of melanoma, including Stage IV, Stage III, Recurrent, Metastatic, and Melanoma. It works by increasing the ability of the immune system to recognize cancer cells and kill them, through the expression of HLA-B7 and β2 microglobulin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}